Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients

Schirrmacher, Volker

doi:10.3390/ijms18051103

Cited by 35 publications

(28 citation statements)

References 98 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NDV in combination with IL-2 was found to be especially T cell stimulatory which increases the anti-tumor capacity. A strong type 1 interferon response is induced in non-permissive species, such as humans, which results in the anti-neoplastic and immune stimulatory properties observed with NDV infection [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

A review of virulent Newcastle disease viruses in the United States and the role of wild birds in viral persistence and spread

Brown¹,

Bevins

2017

Vet Res

115

116

View full text Add to dashboard Cite

Newcastle disease is caused by virulent strains of Newcastle disease virus (NDV), which causes substantial morbidity and mortality events worldwide in poultry. The virus strains can be differentiated as lentogenic, mesogenic, or velogenic based on a mean death time in chicken embryos. Currently, velogenic strains of NDV are not endemic in United States domestic poultry; however, these strains are present in other countries and are occasionally detected in wild birds in the U.S. A viral introduction into domestic poultry could have severe economic consequences due to the loss of production from sick and dying birds, the cost of control measures such as depopulation and disinfection measures, and the trade restrictions that would likely be imposed as a result of an outbreak. Due to the disease-free status of the U.S. and the high cost of a potential viral incursion to the poultry industry, a qualitative risk analysis was performed to evaluate the vulnerabilities of the U.S. against the introduction of virulent strains of NDV. The most likely routes of virus introduction are explored and data gathered by several federal agencies is provided. Recommendations are ultimately provided for data that would be useful to further understand NDV on the landscape and to utilize all existing sampling opportunities to begin to comprehend viral movement and further characterize the risk of NDV introduction into the U.S.Electronic supplementary materialThe online version of this article (doi:10.1186/s13567-017-0475-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

A review of virulent Newcastle disease viruses in the United States and the role of wild birds in viral persistence and spread

Brown¹,

Bevins

2017

Vet Res

115

116

View full text Add to dashboard Cite

show abstract

“…In the present work we propose that NDV oncolytic therapy could be a good approach for the treatment of a specific subgroup of primary brain tumors. NDV-based antineoplastic therapy has demonstrated to elicit a robust long-term anti-tumor immunity in different preclinical tumor models [ 38 , 39 ]. In the present work, we present a new glioma stratification system based on the type I-IFN cluster genomic expression, that could classify patients as potential responders and non-responders to NDV therapy and possibly other oncolytic viruses.…”

Section: Discussionmentioning

confidence: 99%

Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion

García-Romero

Palacín-Aliana

Esteban-Rubio

et al. 2020

Cells

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive and frequent primary brain tumor in adults with a median overall survival of 15 months. Tumor recurrence and poor prognosis are related to cancer stem cells (CSCs), which drive resistance to therapies. A common characteristic in GBM is CDKN2A gene loss, located close to the cluster of type I IFN genes at Ch9p21. Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic and immunostimulatory properties that has been proposed for the treatment of GBM. We have analyzed the CDKN2A-IFN I gene cluster in 1018 glioma tumors and evaluated the NDV oncolytic effect in six GBM CSCs ex vivo and in a mouse model. Our results indicate that more than 50% of GBM patients have some IFN deletion. Moreover, GBM susceptibility to NDV is dependent on the loss of the type I IFN. Infection of GBM with an NDV-expressing influenza virus NS1 protein can overcome the resistance to oncolysis by NDV of type I-competent cells. These results highlight the potential of using NDV vectors in antitumor therapies.

show abstract

“…This is a large (150–400 nm), single-stranded-RNA virus that is a member of the Paramyxoviridae family 114 . Infection with a Newcastle disease virus activates the innate immune system and also causes cancer cell apoptosis, which serves to facilitate the conversion from an immune-suppressive tumor microenvironment into an inflammatory environment with immune effectors capable of anti-tumor effects 6 .…”

Section: Main Textmentioning

confidence: 99%

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

Sivanandam

LaRocca

Chen

et al. 2019

Molecular Therapy - Oncolytics

111

113

View full text Add to dashboard Cite

Cancer immunotherapy and the emergence of immune checkpoint inhibitors have markedly changed the treatment paradigm for many cancers. They function to disrupt cancer cell evasion of the immune response and activate sustained anti-tumor immunity. Oncolytic viruses have also emerged as an additional therapeutic agent for cancer treatment. These viruses are designed to target and kill tumor cells while leaving the normal cells unharmed. As part of this process, oncolytic virus infection stimulates anti-cancer immune responses that augment the efficacy of checkpoint inhibition. These viruses have the capability of transforming a "cold" tumor microenvironment with few immune effector cells into a "hot" environment with increased immune cell and cytokine infiltration. For this reason, there are multiple ongoing clinical trials that combine oncolytic virotherapy and immune checkpoint inhibitors. This review will detail the key oncolytic viruses in preclinical and clinical studies and highlight the results of their testing with checkpoint inhibitors. CTLA-4 CTLA-4, also known as CD152, is an inhibitory molecule on the surface of activated T cells 12 that inhibits the binding of B7 to CD28. 13 Its mechanism functions to halt the initial stage of naive T cell activation in the lymph nodes and results in decreased T cell responses. 14 Anti-CTLA-4 antibodies are designed to block

show abstract

Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients

Cited by 35 publications

References 98 publications

A review of virulent Newcastle disease viruses in the United States and the role of wild birds in viral persistence and spread

A review of virulent Newcastle disease viruses in the United States and the role of wild birds in viral persistence and spread

Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

Contact Info

Product

Resources

About